CAS No.: 2455427-91-3
Molecular Formula: Undisclosed | Molecular Weight: Undisclosed
Dosage Form: Oral Tablet | Manufacturer: AstraZeneca
Product Overview
AZD-0780 (Laroprovstat) is an oral small-molecule PCSK9 inhibitor developed by AstraZeneca, with excellent lipid-lowering efficacy and good safety, currently in Phase Ⅲ clinical trials globally.
Mechanism of Action
• Specifically binds to the C-terminal of PCSK9, avoiding competition with LDL receptors, thereby increasing LDL-C clearance and reducing blood lipid levels effectively.
• It has a half-life of 40 hours and no food effect, which can stably reduce LDL-C levels and lower the risk of atherosclerotic cardiovascular disease (ASCVD).
Indications
In Phase Ⅲ Clinical Trials: Primary hypercholesterolemia, mixed dyslipidemia, especially for patients with high LDL-C who fail to reach targets with statin therapy or are statin-intolerant.
China [CN] 
Click enlarge Image